Valneva SE (VALN) Return on Capital Employed (2022 - 2026)
Valneva SE (VALN) posted quarterly Return on Capital Employed of 34.27% for Q1 2026, down 1847.0% year-on-year from 1.96% in Q1 2025, and down 37.9% on a QoQ basis from 24.85% in Q4 2025.
Valneva SE (VALN) Return on Capital Employed (2022 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Return on Capital Employed for 5 consecutive years, with 34.27% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed fell 1847.0% year-over-year to 34.27% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.27% (down 1847.0% YoY) and the FY2025 annual result came in at 23.04%, down 2669.0% from the prior year.
- Return on Capital Employed fell to 34.27% in Q1 2026 per VALN's latest filing, from 24.85% in the prior quarter.
- Over the last five years, Return on Capital Employed for VALN reached as high as 35.31% in Q3 2022 and fell as low as 39.85% in Q2 2022.
- A 5-year average of 14.43% and a median of 15.8% in 2025 frame the typical range for Return on Capital Employed.
- The largest YoY upside for Return on Capital Employed was 4046 bps in 2023 against a maximum downside of 7153 bps in 2023.
- Year by year, Return on Capital Employed stood at 29.67% in 2022, then advanced by 17 bps to 24.77% in 2023, then soared by 114 bps to 3.39% in 2024, then plunged by 834 bps to 24.85% in 2025, then slumped by 38 bps to 34.27% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 34.27%, 24.85%, and 24.14% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -34.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.27% |
| Dec 31, 2025 | -24.85% |
| Sep 30, 2025 | -24.14% |
| Jun 30, 2025 | -14.26% |
| Mar 31, 2025 | -15.80% |
| Dec 31, 2024 | 3.39% |
| Sep 30, 2024 | 2.43% |
| Jun 30, 2024 | -0.12% |
| Mar 31, 2024 | 0.74% |
| Dec 31, 2023 | -24.77% |
| Sep 30, 2023 | -36.22% |
| Jun 30, 2023 | 0.62% |
| Mar 31, 2023 | -32.59% |
| Dec 31, 2022 | -29.67% |
| Sep 30, 2022 | 35.31% |
| Jun 30, 2022 | -39.85% |
| Mar 31, 2022 | -11.21% |